The Contribution of the Minimal Promoter Element to the Activity of Synthetic Promoters Mediating CAR Expression in...

Area of Science:

• Immunology
• Molecular Biology
• Cancer Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy is a growing field in cancer treatment.
• CAR T therapies, including armored CARs, require precise control over transgene expression levels.
• Previous work established the Chimeric Antigen Receptor Tumor Induced Vector (CARTIV) platform for spatial and temporal transgene control.

Purpose of the Study:

• To introduce a new level of customization to the CARTIV promoter platform.
• To evaluate the impact of different minimal promoter strengths on CAR expression and T cell function.
• To demonstrate an easily integrable gene regulation strategy for CAR T systems.

Main Methods:

• Testing the functionality of three minimal promoters with varying strengths.
• Analyzing CAR expression levels resulting from different promoter activities.
• Assessing primary T cell function in response to varying CAR expression.

Main Results:

• Demonstrated that different minimal promoters yield distinct levels of CAR expression.
• Showcased varying degrees of primary T cell function correlating with CAR expression levels.
• Validated a new layer of gene regulation within the CARTIV platform.

Conclusions:

• The developed promoter platform offers enhanced customization for CAR T gene regulation.
• This strategy allows for fine-tuning of CAR expression and T cell activity.
• The approach is readily applicable to existing CAR T cell therapies for cancer treatment.